Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
grade C 18.41 1.27% 0.23
VCEL closed down 5.95 percent on Friday, March 22, 2019, on 78 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Down
See historical VCEL trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 1.27%
Mar 22 180 Bearish Setup Bearish Swing Setup 1.27%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 1.27%
Mar 22 Stochastic Reached Oversold Weakness 1.27%
Mar 22 BB Squeeze Ended Range Expansion 1.27%
Mar 22 Lower Bollinger Band Touch Weakness 1.27%
Mar 22 Oversold Stochastic Weakness 1.27%
Mar 21 50 DMA Support Bullish -4.76%
Mar 21 Bullish Engulfing Bullish -4.76%
Mar 21 Expansion Pivot Buy Setup Bullish Swing Setup -4.76%

Older signals for VCEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biopharmaceutical Medical Specialties Stem Cells Cell Therapy Burns Cartilage Knee Severe Diseases
Is VCEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 8.95
Average Volume 650,160
200-Day Moving Average 14.5982
50-Day Moving Average 18.4252
20-Day Moving Average 19.41
10-Day Moving Average 19.257
Average True Range 0.8242
ADX 15.11
+DI 15.4866
-DI 23.5709
Chandelier Exit (Long, 3 ATRs ) 18.5274
Chandelier Exit (Short, 3 ATRs ) 18.6726
Upper Bollinger Band 20.6719
Lower Bollinger Band 18.1481
Percent B (%b) 0.01
BandWidth 13.002576
MACD Line 0.0815
MACD Signal Line 0.3094
MACD Histogram -0.2279
Fundamentals Value
Market Cap 596.72 Million
Num Shares 32.8 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -17.48
Price-to-Sales 2.75
Price-to-Book 10.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.89
Resistance 3 (R3) 20.05 19.64 19.61
Resistance 2 (R2) 19.64 19.20 19.56 19.51
Resistance 1 (R1) 18.91 18.94 18.71 18.75 19.41
Pivot Point 18.50 18.50 18.40 18.42 18.50
Support 1 (S1) 17.77 18.06 17.57 17.61 16.95
Support 2 (S2) 17.36 17.80 17.28 16.85
Support 3 (S3) 16.63 17.36 16.76
Support 4 (S4) 16.47